News

Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026

First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha

Benzinga·04:05ATNM▲+1.4%

Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?

Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.

Benzinga·09:11ATNM▲+1.4%

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial clinical results from the first‑in‑human Phase 1 study of ATNM‑400 in metastatic castration‑resistant prostate cancer (mCRPC). The findings, presented in an oral presentation on October 19 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna,

Yahoo·08:00

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results demonstrating the broad antitumor potential of ATNM-400 across non-small cell lung cancer (NSCLC), colorectal cancer and ovarian cancer models. The findings were presented in an oral presentation and two e-posters at the 39th Annual Congress of the European Association of Nucle

Yahoo·07:30ATNM▲+1.4%

Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results

Benzinga·03:32

Actinium Pharmaceuticals, Inc. (ATNM) Presents at European Association of Nuclear Medicine Annual Congress 2026 - Slideshow

SeekingAlpha·12:00ATNM▲+1.4%

Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today reminded investors and the scientific community that clinical and preclinical data for ATNM-400 will be presented today at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 17–21, 2026, in Vienna, Austria.

Yahoo·07:30ATNM▲1.4%

Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21

First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to feature ATNM-400

Benzinga·03:37ATNM▲+1.4%

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement equity awards to Matt David, M.D., the Company's newly appointed Chief Financial Officer, and Sean Maenpaa, the Company's newly appointed Senior Vice President, Business Development.

Yahoo·17:00ATNM▲+1.4%

ATNM: Introduction to Radiopharmaceuticals

By John Vandermosten, CFA NYSE: ATNM READ THE FULL ATNM NOTE Following our recent initiation of coverage for Actinium Pharmaceuticals, Inc. (NYSE: ATNM), this research note provides life sciences investors with an introduction to the radiopharmaceutical industry. We examine the science, clinical applications and manufacturing requirements shaping the sector, highlighting both its therapeutic

Yahoo·12:02ATNM

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced three presentations, including an oral presentation and two e-posters, highlighting preclinical data supporting ATNM-400's broad potential at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), October 17–21, 2026, in Vienna, Austria.

Yahoo·08:30ATNM▲+1.4%

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Sean Maenpaa as Senior Vice President, Business Development, effective October 12, 2026. Mr. Maenpaa will lead the Company's business development activities, including out-licensing, partnering and collaboration transactions, in-licensing opportunities, and broader corporate development strategy.

Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM

Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal cancer data

Benzinga·04:37ATNM▲+1.4%

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that an oral presentation with early results from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC) will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), October 17–21, 2026, in Vienna, Austria.

Yahoo·08:30ATNM▲+1.4%

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer. Dr. David will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.

Actinium Pharmaceuticals To Present Early Phase 1 Clinical Data For ATNM-400 In Metastatic Prostate Cancer At EANM 2026

Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation of

Benzinga·04:38ATNM▲+1.4%

ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio

By John Vandermosten, CFA NYSE: ATNM READ THE FULL ATNM RESEARCH REPORT We are initiating coverage of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) and assign a valuation of $4.00 per share. This valuation is based on our estimates for successful development, approval, and commercialization of ATNM-400 in solid tumors, Actimab-A, Iomab-ACT, and Iomab-B in acute myeloid leukemia (AML), solid tumors,

Yahoo·05:08ATNM▲+1.4%

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology (NASDAQ:PDSB)

Benzinga·09:06

Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacity And Clinical Milestones Into 2027

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents

Benzinga·13:05ATNM▲+1.4%

Actinium Pharmaceuticals Receives NYSE American Compliance Plan Acceptance, Granted Until Nov. 27, 2027 To Regain Listing Compliance

American LLC ("NYSE American") that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the "Company

Benzinga·13:04ATNM▲+1.4%

Actinium Pharmaceuticals Q2 EPS $0.89 Beats $(0.21) Estimate, Sales $35.000M

Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $(0.21) by 523.81 percent. This is a 504.55 percent increase over losses of $(0.22) per

Benzinga·02:47ATNM▲+1.4%